公开(公告)号：US11628197B2

公开(公告)日：2023-04-18

申请号：US17306937

申请日：2021-05-03

申请人： Bioved Pharmaceuticals, Inc.

发明人： Deepa Chitre ,  Debendranath Dey ,  Satej R Nadkarni

IPC分类号： A61K36/9066 ,  A61K36/324 ,  A61K31/25 ,  A61K45/06 ,  A61K36/268 ,  A61K31/375 ,  A61K31/315 ,  A61K31/197

摘要： Methods and compounds for preventing and arresting COVID-19 morbidity and mortality, via inhibition of Interleukin-6, TNF-alpha, and other cytokines, and via reduction of C-reactive proteins are provided. Analyses of patients with COVID-19 complicated by ARDS, for example, show highly activated cytotoxic T-cells, resulting from hyperactivation of the immune system. A significant surge of Interleukin-6 (IL-6), TNF-α, and other cytokines are thought to be mediators of this enhanced T-cell activity, and runaway inflammation that are dangerous or fatal to the patient. Example oral formulations dubbed BV-4051 and Artovid-20 provide prophylaxis and treatment of these conditions caused by COVID-19 disease. The example formulations contain plant extracts boosting the human immune system and targeting the detrimental effects of the SARS-CoV-2 virus in its various strains.

公开(公告)号：US20150164972A1

公开(公告)日：2015-06-18

申请号：US14462553

申请日：2014-08-18

申请人： BIOVED PHARMACEUTICALS, INC.

发明人： DEEPA CHITRE ,  DEBENDRANATH DEY

IPC分类号： A61K36/9068 ,  A61K36/48 ,  A61K36/185 ,  A61K36/68 ,  A61K36/53 ,  A61K36/81 ,  A61K36/9066

CPC分类号： A61K36/9068 ,  A61K36/185 ,  A61K36/48 ,  A61K36/53 ,  A61K36/80 ,  A61K36/81 ,  A61K36/9066 ,  A61K2236/00 ,  A61K2300/00

摘要： A method of obtaining one or more fractions from one or more plants is disclosed. The method includes subjecting one or more parts of the one or more plants to hydro-alcoholic extraction in presence of a water-insoluble solvent to obtain one or more extracts. The method further includes subjecting the one or more extracts to one or more of de-pigmentation, de-fatting and detoxification process to obtain the one or more fractions. The one or more fractions thus obtained contain a desired pharmacologically active ingredient in concentration greater than concentrations of other pharmacologically active ingredients present in the at least one fraction. Further, the one or more fractions are less toxic as compared with corresponding one or more fractions obtained by conventional methods. In addition, the one or more fractions are therapeutically more effective in various diseases as compared to one or more fractions obtained by conventional methods.

摘要翻译： 公开了从一种或多种植物获得一种或多种级分的方法。 该方法包括使一种或多种植物的一个或多个部分在水不溶性溶剂存在下进行水 - 醇提取以获得一种或多种提取物。 所述方法进一步包括使一种或多种提取物经历一种或多种脱色素，去脂肪和解毒过程以获得一种或多种级分。 由此获得的一种或多种级分含有浓度大于存在于至少一个级分中的其它药理活性成分的浓度的所需药理活性成分。 此外，与通过常规方法获得的相应的一种或多种级分相比，一种或多种级分的毒性较小。 此外，与通过常规方法获得的一种或多种级分相比，一种或多种级分在各种疾病中治疗上更有效。

公开(公告)号：US20230226082A1

公开(公告)日：2023-07-20

申请号：US17985097

申请日：2022-11-10

申请人： Bioved Pharmaceuticals, Inc.

发明人： Deepa Chitre ,  Debendranath Dey ,  Satej R Nadkarni

IPC分类号： A61K31/585 ,  A61K31/19 ,  A61K31/12 ,  A61K36/9068 ,  A61K36/9066 ,  A61K36/324 ,  A61K36/81 ,  A61K31/675 ,  A61K31/4025 ,  A61K31/375 ,  A61K33/30 ,  A61K31/198 ,  A61K9/20 ,  A61K9/16 ,  A61P31/14 ,  A61P27/00

CPC分类号： A61K31/585 ,  A61K31/19 ,  A61K31/12 ,  A61K36/9068 ,  A61K36/9066 ,  A61K36/324 ,  A61K36/81 ,  A61K31/675 ,  A61K31/4025 ,  A61K31/375 ,  A61K33/30 ,  A61K31/198 ,  A61K9/2059 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/1611 ,  A61K9/1652 ,  A61P31/14 ,  A61P27/00 ,  A61K2236/333 ,  A61K2236/53

摘要： Methods and formulations for treating and preventing LONG COVID sequelae are provided. An example method treats loss of smell and taste from SARS-CoV-2 infection, including assessing the patient, administering a composition with dosage between 1750-3600 mg per day, wherein the composition comprises a mixture of at least a withanolide-A, a boswellic acid, a [6]-gingerol, and a curcuminoid. Another example method treats memory loss or brain fog from SARS-CoV-2 infection, including assessing the patient, and administering a regenerative and neuroprotective composition comprising a mixture of withanoside VI, withanolide A, a Boswellia serrata plant, a Zingiber officinale rhizome, and a Curcuma longa rhizome. The compositions were found effective, achieving statistical significance in a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial.

公开(公告)号：US20210338765A1

公开(公告)日：2021-11-04

申请号：US17306937

申请日：2021-05-03

申请人： Bioved Pharmaceuticals, Inc.

发明人： DEEPA CHITRE ,  DEBENDRANATH DEY ,  SATEJ R. NADKARNI

IPC分类号： A61K36/9066 ,  A61K36/268 ,  A61K36/324 ,  A61K45/06 ,  A61K31/375 ,  A61K31/315 ,  A61K31/197 ,  A61K31/25

摘要： Methods and compounds for preventing and arresting COVID-19 morbidity and mortality, via inhibition of Interleukin-6, TNF-alpha, and other cytokines, and via reduction of C-reactive proteins are provided. Analyses of patients with COVID-19 complicated by ARDS, for example, show highly activated cytotoxic T-cells, resulting from hyperactivation of the immune system. A significant surge of Interleukin-6 (IL-6), TNF-α, and other cytokines are thought to be mediators of this enhanced T-cell activity, and runaway inflammation that are dangerous or fatal to the patient. Example oral formulations dubbed BV-4051 and Artovid-20 provide prophylaxis and treatment of these conditions caused by COVID-19 disease. The example formulations contain plant extracts boosting the human immune system and targeting the detrimental effects of the SARS-CoV-2 virus in its various strains.

公开(公告)号：US20170007625A1

公开(公告)日：2017-01-12

申请号：US14627652

申请日：2015-02-20

申请人： Bioved Pharmaceuticals, Inc.

发明人： DEEPA CHITRE ,  DEBENDRANATH DEY

IPC分类号： A61K31/573 ,  A61K31/4402 ,  A61K31/415

CPC分类号： A61K31/573 ,  A61K31/415 ,  A61K31/4402 ,  A61K36/324 ,  A61K36/81 ,  A61K36/9066 ,  A61K36/9068 ,  A61K2300/00

摘要： The invention provides method and composition for alleviating one or more symptoms associated with a medical condition mediated by one or more of a cyclooxygenase, a pro-inflammatory cytokine, and a pro-inflammatory enzyme. The method includes administering an effective amount of a composition to a person suffering from the medical condition. The composition essentially includes a set of plant extracts. The set of plant extracts include an extract of Withania somnifera, an extract of Boswellia serrata, an extract of Curcuma longa, and an extract of Zingiber officinale. Wherein, one or more extracts of the set of plant extracts includes one or more desired active ingredient in an amount greater than an amount of other active ingredients present in the one or more extracts. The composition can also be used as combination therapy with any other known anti-inflammatory agents.

摘要翻译： 本发明提供了用于减轻与由一种或多种环加氧酶，促炎细胞因子和促炎酶介导的医学病症相关的一种或多种症状的方法和组合物。 该方法包括向患有该疾病的患者施用有效量的组合物。 组合物基本上包括一组植物提取物。 一组植物提取物包括檀香皂提取物，芥子油提取物，姜黄提取物和姜黄提取物。 其中，所述一组植物提取物中的一种或多种提取物包含大于所述一种或多种提取物中存在的其它活性成分的量的一种或多种所需活性成分。 组合物也可以与任何其它已知的抗炎剂组合使用。

公开(公告)号：US20140363526A1

公开(公告)日：2014-12-11

申请号：US14298524

申请日：2014-06-06

申请人： Bioved Pharmaceuticals, Inc.

发明人： DEEPA CHITRE ,  NARENDRA BHATT ,  DEBENDRANATH DEY ,  SUNETRA CHASKAR

IPC分类号： A61K36/48 ,  A61K36/185 ,  A61K36/19

CPC分类号： A61K36/48 ,  A61K36/185 ,  A61K36/19 ,  A61K36/47 ,  A61K2236/00 ,  A61K2300/00

摘要： A composition of matter comprising a synergistic formulation of plant extracts for hepatic and adrenal disorders is provided. In an implementation, an example extraction method for concentrating pharmacologically active fractions of plants provides a synergistically active compound containing approximately 5%-25% extract of Andrographis paniculata, approximately 10%-30% extract of Boerhavia diffusa, approximately 25%-50% extract of Phyllanthus niruri, and approximately 15%-40% extract of Tephrosia purpurea. The synergistically active compound provides greater therapeutic benefit than the individual ingredients alone, or the combined ingredients in different concentration ranges. The synergistic formulation may also be used for treatment of other medical conditions.

摘要翻译： 提供了包含用于肝和肾上腺疾病的植物提取物的协同制剂的物质组合物。 在一个实施方案中，用于浓缩植物药理活性级分的实施例提取方法提供了协同活性化合物，其含有大约5％-25％的穿心莲提取物，大约10％-30％的波尔哈维酵母提取物，约25％-50％的提取物 （Phyllanthus niruri），以及约15％-40％Tephrosia purpurea的提取物。 协同活性化合物比单独的单独成分或不同浓度范围的组合成分提供更大的治疗益处。 协同制剂也可用于治疗其他医疗条件。